Full Press Release Details
IDEAYA Biosciences Announces Selection of Move Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP Deletion Squamous Non Small Cell Lung Cancer.
IDYA
IDEAYA Biosciences Announces Selection of Move Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP Deletion Squamous Non Small Cell Lung Cancer
Key Takeaway: IDEAYA Biosciences Announces Selection of Move Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP Deletion Squamous Non Small Cell Lung Cancer
Price reaction · baseline $37.13 (2024-04-19 close) · 2 other IDYA headline(s) in the window, move may be shared
day 0 close
+1.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma